clear
Friday September 22nd, 2017 7:30AM

Johnson & Johnson says pricing competition squeezed 1Q sales

By The Associated Press
Related Articles
  Contact Editor

Increased pressure to cut medicine prices and an industry-wide slowdown in consumer health product sales is hurting health care giant Johnson & Johnson.

Those factors, along with a bigger tax bill than a year ago, trimmed J&J's first-quarter profit slightly, but it still gave a rosier financial forecast for the year.

The world's biggest maker of health care products cited its biggest-ever acquisition — the pending $30 billion purchase of Swiss biopharmaceutical company Actelion — for the raised forecast. That deal's expected to close during the current quarter. J&J also benefited from several smaller acquisitions and from the ongoing restructuring of its medical device segment, begun in early 2016.

Revenue was crimped by slower growth in many consumer health product categories and by payers demanding bigger rebates off the prices of certain prescription drugs, Chief Financial Officer Dominic Caruso said in an interview. Caruso said drugs with significant competition, particularly cardiovascular, diabetes and other primary care drugs, were particularly hurt by the pricing pressure.

"The diabetes market is very price sensitive, and (net) prices have been declining for some time," Caruso noted.

That's why J&J has been exploring the sale of its diabetes care businesses, which make test strips and insulin pumps, but will continue selling diabetes pill Invokana, whose sales fell 13 percent in the quarter to $284 million.

The New Brunswick, New Jersey-based company on Tuesday reported net income of $4.42 billion, or $1.61 per share, down from $4.46 billion, or $1.59 per share, a year earlier.

Earnings, adjusted for one-time costs, came to $1.83 per share, six cents above Wall Street expectations. Revenue totaled $17.77 billion, up 1.6 percent but below Street forecasts for $18.01 billion.

In late-morning trading, J&J shares dropped $4.62, or 3.7 percent, to $121.10.

Sales in J&J's prescription drug business rose 0.8 percent to $8.3 billion.

But top seller Remicade, an injected biologic drug for Crohn's disease, rheumatoid arthritis and other immune disorders, saw sales decrease 6 percent to $1.7 billion.

Near copy, or "biosimilar," versions of Remicade have cut into its sales in Europe, where they've been available for much longer than in the U.S.

Caruso said the launch late last year of Pfizer Inc.'s Inflectra, a biosimilar of Remicade, has had little impact on sales in the U.S. Doctors there are hesitant to prescribe biosimilars, which are relatively new to the U.S. market, for patients doing well on Remicade.

The Tylenol maker's consumer product sales rose 1 percent to $3.3 billion, while sales of medical devices and diagnostic equipment increased 3 percent to $6.3 billion.

"The company performed mediocrely in two key areas — pharmaceuticals and consumer products. It managed expenses well, but to continue to increase profits, it has to generate better sales increases," Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan's Ross School of Business, wrote in an email.

J&J reported spending in the quarter rose only a percent or two for manufacturing, marketing, administration and research and development.

"We believe J&J has a solid new drug pipeline, which, along with the Actelion acquisition, should support long-term growth," Edward Jones analyst Ashtyn Evans, who has a "Buy" recommendation on J&J, wrote to investors. But she called the quarterly results "mixed," with "disappointing" overall growth.

Johnson & Johnson said it now expects full-year earnings in the range of $7 to $7.15 per share, up from its January forecast of $6.93 to $7.08 per share. Analysts had been expecting $7.07 per share, on average. J&J also increased its revenue forecast to a range of $75.4 billion to $76.1 billion, up from $74.1 billion to $74.8 billion.

"They're growing very, very rapidly," Caruso said, on sales of Tracleer and other drugs for dangerously high blood pressure in the lungs, and Actelion has experimental medicines for multiple sclerosis and infections in late patient testing.

_____

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma .

  • Associated Categories: Associated Press (AP), AP Health, AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2017 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Before the ax, Comey was pushing Trump-Russia probe harder
Days before he was fired by Donald Trump, FBI Director James Comey asked for more resources from the Justice Department to pursue the investigation into Russia's election meddling and the possible involvement of Trump associates
3:18AM ( 7 minutes ago )
Officials from Arctic nations meet amid drilling concerns
Officials from the world's eight Arctic nations will meet in Alaska amid concerns about the sensitive region after President Trump called for more oil drilling and development.
2:51AM ( 34 minutes ago )
Americans split along party lines on firing of FBI director
Americans are divided along party lines on President Donald Trump's dramatic firing of FBI Director James Comey with Republicans and Trump supporters seeing it as necessary and Democrats viewing it with suspicion
2:47AM ( 38 minutes ago )
Associated Press (AP)
Tunnel collapse renews safety concerns about nuclear sites
The collapse of a tunnel containing radioactive waste at the Hanford nuclear weapons complex underscored what critics have long been saying: The toxic remnants of the Cold War are being stored in haphazard and unsafe conditions around the country
10:27PM ( 4 hours ago )
Tunnel collapse renews safety concerns about nuclear site
Thousands of workers at the Hanford Nuclear Reservation were told to stay home Wednesday as efforts began to plug a hole that developed in the partial collapse of a tunnel containing dangerous radioactive waste from the building of nuclear bomb materials.
12:22PM ( 15 hours ago )
Trump delaying decision on Paris climate deal
Top White House advisers have postponed a meeting to discuss whether the United States should withdraw from the landmark international climate deal struck in Paris
4:07AM ( 23 hours ago )
AP Health
Snapchat's growth stalls in Facebook's shadow in 1Q report
Facebook's shadow continues to hang over Snapchat as its parent company reports disappointing numbers
12:13AM ( 3 hours ago )
Asian stocks mostly higher in quiet trading; oil prices gain
Asian stocks are trading moderately higher with few data reports to move the markets
12:03AM ( 3 hours ago )
Snapchat's growth stalls in Facebook's shadow; stock plunges
Facebook's shadow continues to hang over Snapchat as its parent company reports disappointing numbers
10:07PM ( 5 hours ago )
AP Business
Whole Foods shakes up board as key sales figure falls again
Whole Foods shakes up its board, announces cost-cutting plan as a key sales figure keeps falling
6:31PM ( 8 hours ago )
Reporter arrested while trying to question Cabinet member
Police in West Virginia's Capitol have arrested a journalist who they said was trying "aggressively" to get past Secret Service agents and yelling questions at U.S. Health and Human Services Secretary Tom Price
5:43PM ( 9 hours ago )
AP releases in-depth review of its coverage of Nazi Germany
The Associated Press has conducted an in-depth review of its operations in Nazi Germany, concluding the news agency acted as "forthrightly and independently as possible."
5:06PM ( 10 hours ago )
AP Business - Corporate News
Environmentalists triumph as Senate upholds drilling rule
Environmentalists notched a rare win in the Republican-led Senate Wednesday as a GOP effort to reverse an Obama-era rule restricting harmful methane emissions unexpectedly failed
3:49PM ( 11 hours ago )
European Central Bank's Draghi cautiously upbeat on eurozone
The head of the European Central Bank says risks to the strengthening recovery in the 19-country have diminished _ but insisted it's too early to declare victory and start withdrawing the bank's stimulus measures
8:29AM ( 18 hours ago )
Abortion foes cheer series of advances, as opponents protest
From the U.S. Capitol and the White House to far-flung battlegrounds in Arizona, Iowa and elsewhere, it's been a dramatic two weeks in the debate over access to abortion and birth control
3:59PM ( 1 day ago )
AP Business - Industries
Senate Dems ask GOP to drop their plan to repeal 'Obamacare'
Senate Republicans trying to craft a health care overhaul are discussing how to ease provisions in the House-passed bill phasing out President Barack Obama's expansion of Medicaid
2:06PM ( 1 day ago )
Drugmaker Valeant tops 1Q profit forecasts, chops debt again
Valeant Pharmaceuticals beats 1Q profit expectations, misses revenue forecasts
8:28AM ( 1 day ago )
Valeant tops 1Q profit forecasts
Valeant Pharmaceuticals beats 1Q profit expectations, misses revenue forecasts
7:50AM ( 1 day ago )
AP Business - Health Care
Before the ax, Comey was pushing Trump-Russia probe harder
Days before he was fired by Donald Trump, FBI Director James Comey asked for more resources from the Justice Department to pursue the investigation into Russia's election meddling and the possible involvement of Trump associates
3:18AM ( 8 minutes ago )
Officials from Arctic nations meet amid drilling concerns
Officials from the world's eight Arctic nations will meet in Alaska amid concerns about the sensitive region after President Trump called for more oil drilling and development.
2:51AM ( 34 minutes ago )
Americans split along party lines on firing of FBI director
Americans are divided along party lines on President Donald Trump's dramatic firing of FBI Director James Comey with Republicans and Trump supporters seeing it as necessary and Democrats viewing it with suspicion
2:47AM ( 38 minutes ago )
Penguins just now finding their groove going into East final
The defending Stanley Cup-champion Penguins are just now finding their groove going into the Eastern Conference final against the Senators
2:46AM ( 39 minutes ago )
LEADING OFF: Keuchel, Bundy seek 6th wins; Trout eyes return
LEADING OFF: Keuchel, Bundy seek 6th wins; Trout eyes return
2:45AM ( 40 minutes ago )